natgillin/translations-raw huggingface dataset:
VIAGRA 50 mg film-coated tablets 
VIAGRA 50 mg filmom obložene tablete
VIAGRA 50 mg orodispersible tablets 
VIAGRA 50 mg raspadljive tablete za usta
EU/1/98/077/015 (2 film-coated tablets) EU/1/98/077/010 (4 film-coated tablets) EU/1/98/077/011 (8 film-coated tablets) EU/1/98/077/012 (12 film-coated tablets) EU/1/98/077/025 (24 film-coated tablets) 
EU/1/98/077/015 (2 filmom obložene tablete) EU/1/98/077/010 (4 filmom obložene tablete) EU/1/98/077/011 (8 filmom obloženih tableta) EU/1/98/077/012 (12 filmom obloženih tableta EU/1/98/077/025 (24 filmom obložene tablete)
Each tablet contains sildenafil citrate equivalent to 100 mg of sildenafil 
Jedna tableta sadrži 100 mg sildenafila u obliku sildenafilcitrata
EU/1/98/077/016 (2 film-coated tablets) EU/1/98/077/017 (4 film-coated tablets) EU/1/98/077/018 (8 film-coated tablets) EU/1/98/077/019 (12 film-coated tablets) 
EU/1/98/077/016 (2 filmom obložene tablete) EU/1/98/077/017 (4 filmom obložene tablete) EU/1/98/077/018 (8 filmom obloženih tableta) EU/1/98/077/019 (12 filmom obloženih tableta)
VIAGRA 50 mg tablets Blue, rounded, diamond-shaped tablets, marked “PFIZER” on one side and “VGR 50” on the other. 
Plava tableta u obliku romba zaobljenih rubova, s oznakom "PFIZER" na jednoj i "VGR 50" na drugoj strani.
VIAGRA 25 mg film-coated tablets Sildenafil 
VIAGRA 25 mg filmom obložene tablete sildenafil
Each tablet contains 50 mg of sildenafil (as the citrate salt). 
Jedna tableta sadrži 50 mg sildenafila (u obliku sildenafilcitrata).
VIAGRA 100 mg film-coated tablets Sildenafil 
VIAGRA 100 mg filmom obložene tablete sildenafil
EU/1/98/077/013 (2 film-coated tablets) EU/1/98/077/002 (4 film-coated tablets) EU/1/98/077/003 (8 film-coated tablets) EU/1/98/077/004 (12 film-coated tablets) 
EU/1/98/077/013 (2 filmom obložene tablete) EU/1/98/077/002 (4 filmom obložene tablete) EU/1/98/077/003 (8 filmom obloženih tableta) EU/1/98/077/004 (12 filmom obloženih tableta)
EU/1/98/077/014 (2 film-coated tablets) EU/1/98/077/006 (4 film-coated tablets) EU/1/98/077/007 (8 film-coated tablets) EU/1/98/077/008 (12 film-coated tablets) EU/1/98/077/024 (24 film-coated tablets) 
EU/1/98/077/014 (2 filmom obložene tablete) EU/1/98/077/006 (4 filmom obložene tablete) EU/1/98/077/007 (8 filmom obloženih tableta) EU/1/98/077/008 (12 filmom obloženih tableta) EU/1/98/077/024 (24 filmom obložene tablete)
VIAGRA 50 mg orodispersible tablets Sildenafil 
VIAGRA 50 mg raspadljive tablete za usta sildenafil
VIAGRA 50 mg film-coated tablets Sildenafil 
VIAGRA 50 mg filmom obložene tablete sildenafil
Each tablet contains sildenafil citrate equivalent to 50 mg of sildenafil. 
Jedna tableta sadrži 50 mg sildenafila u obliku sildenafilcitrata.
Each tablet contains sildenafil citrate equivalent to 50 mg of sildenafil 
Jedna tableta sadrži 50 mg sildenafila u obliku sildenafilcitrata
When a single 100 mg dose of sildenafil was administered with erythromycin, a moderate CYP3A4 inhibitor, at steady state (500 mg twice daily. 
Kod primjene jednokratne doze od 100 mg sildenafila s eritromicinom, umjerenim inhibitorom CYP3A4, u stanju dinamičke ravnoteže (500 mg dva puta dnevno tijekom 5 dana) uočen je 182%-tni porast sustavne izloženosti sildenafilu (AUC).
mouth 
Gluhoća
84 (4 x 21) tablets (multipack) 
84 (4 x 21) tablete (višestruko pakiranje)
Film-coated tablet Oral use blister (PVC/PE/PCTFE/alu) 
100 mg / 40 mg filmom obložena tableta kroz usta blister (PVC/PE/PCTFE/Al)
Your doctor will advise you what to do. 
Vaš liječnik će Vam savjetovati što učiniti.
Increases were approximately two times more likely in females. 
Povećanja su bila približno dva puta vjerojatnija u žena.
Investigator's global assessments of efficacy also showed significant improvement. 
Ispitivačeva opća procjena učinkovitosti je također pokazala značajno poboljšanje.
Very rare (<1/10,000), not known (cannot be estimated from the available data) 
Vrlo rijetko (<1/10 000), nepoznato (ne može se procijeniti iz dostupnih podataka)
Always take Tasmar exactly as your doctor has told you. 
Uvijek uzmite Tasmar točno onako kako Vam je rekao Vaš liječnik.
Your doctor may need to review your treatments. 
Vaš liječnik će možda morati razmotriti Vaša liječenja.
In this case your doctor may perform regular blood tests to monitor how easily your blood clots. 
U tom će slučaju Vaš liječnik redovito provoditi krvne testove kako bi nadzirao koliko se lako zgrušava Vaša krv.
- if you are pregnant or intend to become pregnant. 
- ako ste trudni ili namjeravate zatrudnjeti.
Take it as soon as you remember, then continue to take it at the usual times. 
Uzmite lijek čim se sjetite, a zatim nastavite uzimati u uobičajeno vrijeme.
Accordingly, such patients should not be considered for re-treatment. 
Prema tome, takvi bolesnici se ne bi trebali uzeti u obzir za ponovno liječenje.
However clinical circumstances of these cases were so diverse, that no general conclusions can be drawn from the cases. 
Međutim, kliničke posljedice tih slučajeva bile su toliko različite da se ne mogu izvesti opći zaključci iz slučajeva.
Management of overdose: Hospitalisation is advised. 
Zbrinjavanje predoziranja: savjetuje se hospitalizacija.
Tasmar is administered orally three times daily. 
Tasmar se primjenjuje peroralno tri puta dnevno.
frequency cannot be estimated from the available data 
učestalost se ne može procijeniti iz dostupnih podataka
Sudden onset of sleep during daily activities, in some cases without awareness or warning signs, has been reported very rarely. 
Iznenadni nastup sna tijekom dnevnih aktivnosti, u nekim slučajevima bez svjesnosti ili znakova upozorenja, prijavljen je vrlo rijetko.
Number (proportion) improved on both primary and secondary outcome 
Broj (udio) poboljšanja u oba primarna i sekundarna ishoda
other important symptoms are high fever and mental confusion. 
- drugi važni simptomi su visoka vrućica i mentalna smetenost.
You should check with your doctor or pharmacist if you are unsure. 
Provjerite sa svojim liječnikom ili ljekarnikom ako niste sigurni.
If you develop any symptoms as described above, that you think may be NMS, you should report them to your doctor immediately. 
Ako razvijete bilo koje simptome opisane iznad za koje mislite da bi mogli biti NMS, trebate ih odmah prijaviti svom liječniku.
Tasmar with food and drink and alcohol Tasmar can be taken with or without food. 
Tasmar s hranom, pićem i alkoholom Tasmar se može uzeti sa ili bez hrane.
A diagnosis of NMS should be considered even if not all the above findings are present. 
Treba razmotriti dijagnozu NMS-a čak i ako nisu prisutni svi gore navedeni nalazi.
4.5 Interaction with other medicinal products and other forms of interaction 
4.5 Interakcije s drugim lijekovim i drugi oblici interakcija
Clinical Efficacy and Safety 
Klinička djelotvornost i sigurnost
Tolcapone does not distribute widely into tissues due to its high plasma protein binding (>99.9 %). 
Tolkapon se ne distribuira u tkiva zbog njegova visoka vezivanja na proteine plazme (>99,9 %).
Distribution: The volume of distribution (Vss) of tolcapone is small (9 l). 
Distribucija: volumen distribucije (Vss) tolkapona je mali (9 l).
Additionally late onset hepatitis after approximately 18 months of treatment has been reported rarely. 
Pored toga, kasni nastup hepatitisa nakon približno 18 mjeseci liječenja je rijetko zabilježen.
If this happens notify your doctor. 
Ako se to dogodi, obavijestite svog liječnika.
Primary Outcome 
Primarni ishod
You must tell your doctor if you are pregnant or intend to become pregnant. 
Morate reći svom liječniku ako ste trudni ili namjeravate zatrudnjeti.
Number (proportion) with moderate or marked improvement 
Broj (udio) s umjerenim ili značajnim poboljšanjem
UNIQUE IDENTIFIER - 2D BARCODE 
17. JEDINSTVENI IDENTIFIKATOR-2D BARKOD
Time of day Dose 
Vrijeme dana Doza
The following preventive measures have to be considered. 
Moraju se razmotriti sljedeće preventivne mjere.
What Tasmar is and what it is used for 
Što je Tasmar i za što se koristi
How to take the medication: 
Kako uzimati lijek:
These adverse reactions were predictable based on the known adverse reactions to each of the three drugs individually. 
Te su nuspojave bile predvidljive na temelju poznatih nuspojava svakog od tri lijeka pojedinačno.
Therefore, the following preventive measures have to be considered. 
Stoga se moraju razmotriti sljedeće preventivne mjere.
Do not take a double dose to make up for forgotten individual doses. 
Nemojte uzeti dvostruku dozu kako biste nadoknadili zaboravljenu pojedinačnu dozu.
Always follow the instructions of your doctor about the duration of the treatment with Tasmar. 
Uvijek pratite upute svog liječnika o trajanju liječenja Tasmarom.
If you take more Tasmar than you should 
Ako uzmete više Tasmara nego što ste trebali
Tolcapon e N=75 
Tolkapon e N=75
Other Medicines and Tasmar 
Drugi lijekovi i Tasmar
Talk to your doctor or pharmacist before taking Tasmar. 
Obratite se svom liječniku ili ljekarniku prije nego uzmete Tasmar.
For the treatment of your Parkinson´s disease you already take levodopa. 
Za liječenje Vaše Parkinsonove bolesti već uzimate levodopu.
The increases usually appeared within 6 to 12 weeks of starting treatment, and were not associated with any clinical signs or symptoms. 
Povećanja su se obično javila unutar 6 do 12 tjedana nakon početka liječenja te nisu bila povezana s nikakvim kliničkim znakovima i simptomima.
Reducing the dose of levodopa (see section 4.2) may often mitigate these adverse reactions. 
Smanjenje doze levodope (vidjeti dio 4.2) često može ublažiti te nuspojave.
What Tasmar is and what it is used for What do you need to know before you take Tasmar How to take Tasmar 
Što je Tasmar i za što se koristi Što morate znati prije nego počnete uzimati Tasmar Kako uzimati Tasmar
1 Primary and Secondary Outcome of double-blind Trial Entacapone 
1 Primarni i sekundarni ishodi dvostruko slijepog ispitivanja Entakapon
Tasmar may be taken with or without food (see section 5.2). 
Tasmar se može uzeti sa ili bez hrane (vidjeti dio 5.2).
The primary outcome was the proportion of patients with a 1 or more hour increase in ON time (see Table 1). 
Primarni ishod bio je razmjer bolesnika s 1 ili više sati povećanja u ON vremenu (vidjeti tablicu 1).
This reduction may increase the average concentration of unbound drug two-fold. 
Ovo smanjenje može dvostruko povećati prosječnu koncentraciju nevezanog lijeka.
Since your ability to drive a car or operate machinery may be affected by Parkinson's disease, you should discuss this with your doctor. 
Budući da Vaša sposobnost vožnje automobila ili rada sa strojevima može biti pogođena Parkinsonovom bolešću, trebate o tome razgovarati sa svojim liječnikom.
The magnitude of the effect was dependent on the dose of benserazide. 
Veličina učinka bila je ovisna o dozi benzerazida.
Tasmar should be taken with 1 glass of water. 
Tasmar se treba uzeti s 1 čašom vode.
Increase of alanine aminotransferase 
Povećanje alanin aminotransferaze
Periodic monitoring of liver enzymes cannot reliably predict the occurrence of fulminant hepatitis. 
Periodičko nadziranje jetrenih enzima ne može pouzdano predvidjeti pojavu fulminantnog hepatitisa.
Any other yellow urine discolouring is usually harmless. 
Bilo koja druga žuta promjena boje mokraće je obično bezopasna.
Therefore you must refrain from driving or operating machines until such recurrent episodes and excessive drowsiness have resolved. 
Stoga se morate suzdržati od vožnje i rada na strojevima dok takve ponavljajuće epizode i prekomjerna omamljenost ne prestanu.
An interaction was observed with benserazide, which may lead to increased levels of benserazide and its active metabolite. 
Opažena je interakcija s benzerazidom, koja može voditi do povišenih razina benzerazida i njegovog aktivnog metabolita.
The maximum therapeutic dose of 200 mg three times daily should not be exceeded, as there is no evidence of additional efficacy at higher doses. 
Maksimalna terapijska doza od 200 mg tri puta dnevno se ne smije prekoračiti jer ne postoje dokazi o dodatnoj djelotvornosti pri većim dozama.
Liver injury has occurred most often after 1 month and before 6 months. 
Oštećenje jetre najčešće se javljalo nakon 1 mjeseca i prije 6 mjeseci.
However, it is generally believed that early detection of medicine-induced hepatic injury along with immediate withdrawal of the suspect medication enhances the likelihood for recovery. 
Međutim, općenito se smatra da rano otkrivanje lijekovima izazvanog oštećenja jetre, zajedno s trenutnim ukidanjem suspektnog lijeka, povećava vjerojatnost oporavka.
- Impulse control disorders (inability to resist the impulse of an action that could be harmful). 
- poremećaj kontrole impulsa (nemogućnost odupiranja impulse za neki postupak koji može biti štetan)
Tasmar is not recommended for use in children below the age of 18 due to insufficient data on safety or efficacy. 
Ne preporučuje se primjena Tasmara u djece mlađe od 18 godina zbog nedostatka podataka o sigurnosti i učinkovitosti.
Do not use Tasmar if you notice that the tablets are damaged. 
Tasmar se ne smije primijeniti ako primijetite da su tablete oštećene.
If you go to hospital or if you are prescribed a new medicine, you must tell your doctor that you are taking Tasmar. 
Ako odlazite u bolnicu ili Vam je propisan novi lijek, morate reći Vašem liječniku da uzimate Tasmar.
Biotransformation/Elimination: Tolcapone is almost completely metabolised prior to excretion, with only a very small amount (0.5 % of dose) found unchanged in urine. 
Biotransformacija/Eliminacija: tolkapon se gotovo potpuno metabolizira prije izlučivanja, a tek se mala količina (0,5 % doze) nađe nepromijenjena u urinu.
Tell your doctor if you experience any of these behaviours; these will discuss ways of managing or reducing the symptoms. 
Obavijestite svog liječnika ili ljekarnika ako primijetite bilo koje od ovih ponašanja; oni će razmotriti načine zbrinjavanja ili smanjenja simptoma.
Tasmar may cause rare but potentially fatal liver injury. 
Tasmar može prouzročiti rijetko, ali potencijalno smrtonosno oštećenje jetre.
In general, the average peak levodopa plasma concentration (Cmax) and the time of its occurrence (tmax) were unaffected. 
Općenito, prosječne vršne koncentracije levodope u plazmi (Cmax) i vrijeme njihove pojave (tmax) bili su nepromijenjeni.
The reduction to a putative amine, as well as the subsequent N-acetylation, occurs to a minor extent. 
Redukcija u putativni amin, kao i posljedična N-acetilacija, javlja se u manjem opsegu.
35-959 Rzeszów Poland 
35-959 Rzeszów Poljska
Lactose intolerance: Tasmar contains lactose. 
Intolerancija laktoze: Tasmar sadrži laktozu.
Impulse control disorders: Patients should be regularly monitored for the development of impulse control disorders. 
Poremećaji kontrole impulsa: bolesnike treba redovito nadzirati zbog mogućeg razvoja poremećaja kontrole impulsa.
Isolated cases of either accidental or intentional overdose with tolcapone tablets have been reported. 
Prijavljeni su izolirani slučajevi slučajnog ili namjernog predoziranja tabletama tolkapona.
There is no relevant indication for use in children and adolescents. 
Nema relevantne indikacije za primjenu u djece i adolescenata.
Muscle injury can sometimes cause dark urine. 
Oštećenje mišića može ponekad prouzročiti tamnu mokraću.
Tasmar should not be prescribed until there has been a complete informative discussion of the risks with the patient. 
Tasmar se ne bi smio propisati prije cjelovitog informativnog razgovora s bolesnikom o rizicima.
Isolated cases consistent with NMS have been associated with Tasmar treatment. 
Izolirani slučajevi konzistentni s NMS-om povezivani su s liječenjem Tasmarom.
Studies in healthy volunteers and parkinsonian patients have confirmed that the maximum effect occurs with 100 - 200 mg tolcapone. 
Ispitivanja na zdravim dobrovoljcima i bolesnicima s Parkinsonovom bolešću potvrdila su da se maksimalni učinak javlja sa 100-200 mg tolkapona.
The following doses of Tasmar should be taken 6 and 12 hours later. 
Sljedeće doze Tasmara trebali biste uzeti 6 i 12 sati kasnije.
It should also be noted that female patients may have a higher risk of liver injury. 
Treba također napomenuti da ženski bolesnici imaju veći rizik od oštećenja jetre.
The safety of tolcapone in infants is unknown; therefore, women should not breast-feed during treatment with Tasmar. 
Sigurnost tolkapona za dojenčad je nepoznata; stoga, žene ne bi smjele dojiti tijekom liječenja Tasmarom.
In vitro experiments have shown that tolcapone binds mainly to serum albumin. 
In vitro pokusi pokazali su da se tolkapon vezuje uglavnom na serumski albumin.
After oral administration, 60 % of drug-related material is excreted into urine and 40 % into faeces. 
Nakon peroralne primjene, 60 % tvari povezane s lijekom izlučuje se u urin, a 40 % u feces.
Your doctor will discuss the risks and benefits of taking Tasmar during pregnancy. 
Vaš liječnik će razmotriti rizike i dobrobiti uzimanja Tasmara tijekom trudnoće.
This is due to a decrease in clearance in L-dopa resulting in a prolongation of the terminal elimination half-life (t1/2) of levodopa. 
To je zbog smanjenja klirensa L-dope što rezultira produljenjem terminalnog poluvijeka eliminacije (t1/2) levodope.
The treatment with Tasmar may sometimes lead to disturbances in the way the liver works. 
Liječenje Tasmarom ponekad može dovesti do poremećaja u načinu rada jetre.
The frequency of possible side effects listed below is defined using the following convention: 
Učestalost mogućih nuspojava navedenih ispod definirana je koristeći se sljedećom konvencijom: Vrlo često:
if you develop persistent or severe diarrhoea 
- ako razvijete dugotrajni ili teški proljev.
With 200 mg tolcapone, maximum inhibition of erythrocyte COMT activity is, on average, greater than 80 %. 
S 200 mg tolkapona maksimalna inhibicija aktivnosti eritrocitnog COMT-a je prosječno bila veća od 80 %.
Furthermore a reduction of levodopa dose or termination of therapy may be considered. 
Nadalje se može razmotriti smanjenje doze levodope ili prestanak terapije.
Tasmar has an effect on the symptoms of your Parkinson's disease. 
Tasmar ima učinke na simptome Parkinsonove bolesti.
The main metabolic pathway of tolcapone is conjugation to its inactive glucuronide. 
Glavni metabolički put tolkapona je konjugacija u njegov inaktivni glukuronid.
Before beginning treatment: 
Prije početka liječenja:
Based on the physicochemical properties of the compound, hemodialysis is unlikely to be of benefit. 
Na temelju fizikalno-kemijskih svojstava spoja, nije vjerojatno da će hemodijaliza biti od koristi.
Therefore, clinically relevant interactions involving cytochrome CYP2C9 appear unlikely. 
Stoga se klinički značajne interakcije koje uključuju citokrom CYP2C9 ne čine vjerojatnima.
Do not stop Tasmar or any other Parkinson's medications without telling your doctor as this may increase the risk of NMS. 
Nemojte prekidati liječenje Tasmarom ili bilo kojim drugim lijekom za Parkinsonovu bolest, a da to ne kažete svom liječniku, jer to može povećati rizik od NMS-a.
During dosing with Tasmar 200 mg three times daily, erythrocyte COMT inhibition at trough is 30 % to 45 %, with no development of tolerance. 
Tijekom doziranja Tasmara od 200 mg tri puta dnevno, inhibicija eritrocitnog COMT-a bila je 30 % do 45 %, bez razvoja tolerancije.
Tell your doctor if you or your family/ carer notices you are developing urges or cravings to behave in ways that are unusual for you or you cannot resist the impulse, drive or temptation to carry out certain activities that could harm yourself or others. 
Obavijestite svog liječnika ako Vi ili Vaša obitelj / njegovatelj primijeti da razvijate nagone ili želje da se ponašate na način koji nije uobičajen za Vas ili ne možete odoljeti impulsima, nagonima ili iskušenjima da izvodite određene aktivnosti koje bi mogle naškoditi Vama ili drugima.
The inhibition is closely related to plasma tolcapone concentration. 
Inhibicija je blisko povezana s koncentracijama tolkapona u plazmi.
Tasmar blocks this enzyme and thus slows the breakdown of levodopa. 
Tasmar blokira taj enzim te time usporava razgrađivanje levodope.
p value 95 % CI 
95 % CI
However, no evidence of renal toxicity was observed in the low-dose group. 
Međutim, nisu opaženi dokazi za renalnu toksičnost u skupini koja je primala nisku dozu.
Preclinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction. 
Pretklinički podaci ne ukazuju na poseban rizik za ljude na temelju konvencionalnih ispitivanja sigurnosne farmakologije, toksičnosti ponovljenih doza, genotoksičnosti, kancerogenosti, reproduktivne toksičnosti.
Tolcapone markedly reduces the formation of 3-OMD. 
Tolkapon značajno smanjuje stvaranje 3-OMD-a.
Food delays and decreases the absorption of tolcapone, but the relative bioavailability of a dose of tolcapone taken with a meal is still 80 % to 90 %. 
Hrana odgađa i smanjuje apsorpciju tolkapona, ali je relativna bioraspoloživost doze tolkapona uzete s obrokom još uvijek 80 % do 90 %.
The absolute bioavailability of an oral administration is around 65 %. 
Apsolutna bioraspoloživost oralne primjene je otprilike 65 %.
Therefore, Tasmar should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus. 
Stoga, Tasmar treba primjenjivati tijekom trudnoće samo ako potencijalna korist opravdava potencijalni rizik za fetus.
Furthermore a reduction of levodopa dose or termination of therapy may be considered (see section 4.7). 
Nadalje se može razmotriti smanjenje doze levodope ili prestanak terapije (vidjeti dio 4.7).
Do not reduce or stop taking your medicine unless your doctor tells you. 
Nemojte smanjivati dozu niti prekidati primjenu lijeka, osim ako Vam to kaže liječnik.
You should not start taking Tasmar until your doctor - has described the risks of treatment with Tasmar, - has explained the measures necessary to minimise those risks, - has answered any questions you may have. 
Ne smijete početi uzimati Tasmar ako Vaš liječnik nije - opisao rizike liječenja Tasmarom, - objasnio mjere koje su potrebne da se ti rizici smanje, - odgovorio na sva pitanja koja ste imali.
Diarrhoea associated with Tasmar usually began 2 to 4 months after initiation of therapy. 
Proljev povezan s Tasmarom je obično počinjao 2 do 4 mjeseca nakon početka terapije.
There are no adequate data from the use of tolcapone in pregnant women. 
Nema odgovarajućih podataka o primjeni tolkapona u trudnica.
It should also be noted that female patients may have a higher risk of liver injury (see section 4.8). 
Treba također napomenuti da ženski bolesnici možda imaju veći rizik od oštećenja jetre (vidjeti dio 4.8).
You should only receive Tasmar if your Parkinson's disease is not adequately controlled by the use of other therapies. 
Smijete primati Tasmar samo ako Vaša Parkinsonova bolest nije odgovarajuće kontrolirana primjenom drugih terapija.
If you feel unwell, you should contact your doctor because you may need to take less levodopa. 
Ako se osjećate loše, obratite se svom liječniku jer možda trebate uzimati manje levodope.
When Tasmar was given together with levodopa/carbidopa and desipramine, there was no significant change in blood pressure, pulse rate and plasma concentrations of desipramine. 
Kada se Tasmar davao zajedno s levodopom/karbidopom i desipraminom, nije bilo značajne promjene u krvnom tlaku, brzini pulsa i plazmatskim koncentracijama desipramina.
However, the relationship of renal function and tolcapone pharmacokinetics has been investigated using population pharmacokinetics during clinical trials. 
Međutim, povezanost između funkcije bubrega i farmakokinetike tolkapona bila je istražena pomoću populacijske farmakokinetike tijekom kliničkih ispitivanja.
The t1/2 of tolcapone is approximately 2 hours. 
Tolkapon ima t1/2 od približno 2 sata.
if you are hypersensitive (allergic) to the active substance tolcapone or to any of the other ingredients of Tasmar. 
- ako ste preosjetljivi (alergični) na djelatnu tvar tolkapon ili na bilo koji drugi sastojak Tasmara.
Elderly patients No dose adjustment of Tasmar is recommended for elderly patients. 
Nije preporučena prilagodba doze Tasmara za starije bolesnike.